- Home
- EPRX vs GNLX Comparison
EPRX vs GNLX Comparison
Compare EPRX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- GNLX
- Stock Information
- Founded
- EPRX 2011
- GNLX 2001
- Country
- EPRX Canada
- GNLX United States
- Employees
- EPRX N/A
- GNLX N/A
- Industry
- EPRX
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- EPRX
- GNLX Health Care
- Exchange
- EPRX NYSE
- GNLX Nasdaq
- Market Cap
- EPRX 111.1M
- GNLX 103.6M
- IPO Year
- EPRX N/A
- GNLX 2023
- Fundamental
- Price
- EPRX $3.33
- GNLX $2.40
- Analyst Decision
- EPRX Strong Buy
- GNLX Strong Buy
- Analyst Count
- EPRX 1
- GNLX 4
- Target Price
- EPRX $9.00
- GNLX $18.25
- AVG Volume (30 Days)
- EPRX 24.6K
- GNLX 163.2K
- Earning Date
- EPRX 02-07-2025
- GNLX 11-14-2024
- Dividend Yield
- EPRX N/A
- GNLX N/A
- EPS Growth
- EPRX N/A
- GNLX N/A
- EPS
- EPRX N/A
- GNLX N/A
- Revenue
- EPRX N/A
- GNLX $8,000.00
- Revenue This Year
- EPRX N/A
- GNLX N/A
- Revenue Next Year
- EPRX N/A
- GNLX N/A
- P/E Ratio
- EPRX N/A
- GNLX N/A
- Revenue Growth
- EPRX N/A
- GNLX N/A
- 52 Week Low
- EPRX $2.20
- GNLX $1.60
- 52 Week High
- EPRX $4.08
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- GNLX 40.85
- Support Level
- EPRX N/A
- GNLX $2.48
- Resistance Level
- EPRX N/A
- GNLX $2.80
- Average True Range (ATR)
- EPRX 0.00
- GNLX 0.19
- MACD
- EPRX 0.00
- GNLX -0.03
- Stochastic Oscillator
- EPRX 0.00
- GNLX 15.38
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.